



April 1, 2021

To whom it may concern

Company: Teijin Limited  
Representative: Jun Suzuki, President and CEO  
Stock code: 3401 (First Section, Tokyo Stock Exchange)  
Contact: Tomoko Torii, General Manager  
Investor Relations Department  
TEL: +81-3-3506-4395

### Notice Regarding Completion of Transfer of Japan Sales of Type 2 Diabetes Treatments

Teijin Limited ("Teijin") is pleased to announce that, today, the preconditions to the asset transfer prescribed in the asset transfer agreement that was announced in the Notice Regarding Execution of Asset Transfer Agreement for Transfer of Japan Sales, Intellectual Properties, and Manufacturing and Marketing Approval of Type 2 Diabetes Treatments (Nesina<sup>®</sup>, Liovel<sup>®</sup>, Inisync<sup>®</sup>, and Zafatek<sup>®</sup>) dated February 26, 2021 have been satisfied and the Japan sales of type 2 diabetes treatments manufactured and sold in Japan by Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka; President & CEO: Christophe Weber; hereinafter "Takeda") have been transferred to Teijin's subsidiary Teijin Pharma Limited (Head Office: Chiyoda-ku, Tokyo; President: Ichiro Watanabe; hereinafter "Teijin Pharma").

The sales of the following type 2 diabetes treatments (the "Products") have been transferred:

- Nesina<sup>®</sup> tablets 6.25 mg, 12.5 mg, 25 mg (Generic name: alogliptin benzoate)
- Liovel<sup>®</sup> combination tablets HD, Liovel<sup>®</sup> combination tablets LD (Generic name: alogliptin benzoate/pioglitazone hydrochloride)
- Inisync<sup>®</sup> combination tablets (Generic name: alogliptin benzoate/metformin hydrochloride)
- Zafatek<sup>®</sup> tablets 25 mg, 50 mg, 100 mg (Generic name: trelagliptin succinate)

With the completion of the sales transfer today, Teijin Pharma will henceforth be selling the Products and providing and collecting relevant information in Japan. Also, to ensure stable delivery of the Products to patients, Teijin and Teijin Pharma will continue to work closely with Takeda for a smooth and efficient transfer of the manufacturing and marketing approvals concerning the Products.

- End -